Lipitor Lawsuit News: 270 Lipitor Diabetes Claims Now Pending in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports
New York, New York (PRWEB) March 14, 2014 -- Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) continue to mount in the multidistrict litigation now underway in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to an updated docket report issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on March 13, 2014, 270 claims have been filed in the proceeding on behalf of plaintiffs who allegedly developed new-onset Type 2 diabetes due to their use of the cholesterol-lowering statin. According to court documents, just 56 Lipitor diabetes claims were transferred to the District of South Carolina when the multidistrict litigation was established last month. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm hears from alleged victims of Lipitor and diabetes on a regular basis. It’s not surprising that the number of claims filed in this proceeding has grown so quickly,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit consultations to anyone who may have developed Type 2 diabetes due to the use of this statin medication.
Lipitor Diabetes Allegations
According to court documents, Plaintiffs throughout the country began filing Lipitor lawsuits after the U.S. Food & Drug Administration (FDA) ordered the manufacturers of statins to add new information to their product labels regarding a possible increased risk of Type 2 diabetes. The agency acted after a study published in JAMA: Internal Medicine in January 2012 reported that post-menopausal women treated with drugs like Lipitor were at increased risk of developing new-onset Type 2 diabetes. *
According to their filings, Plaintiffs in Lipitor lawsuits claim that Pfizer Inc. failed to adequately warn patients and doctors about the link between Lipitor and diabetes, and was negligent, careless and/or reckless in its marketing of the cholesterol-lowering drug. They further allege that the company sold Lipitor even though it was aware that the drug could cause patients to develop Type 2 diabetes. Finally, the lawsuits claim that the warnings added to the Lipitor label by Pfizer following the FDA’s 2012 mandate remain inadequate.
Individuals who allegedly developed diabetes due to their use of Lipitor may be entitled to compensation from Pfizer, Inc.Learn more about the possible association between Lipitor and diabetes via Bernstein Liebhard LLP's website. To arrange for a free legal review, please call 800-511-5092.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.lipitorlawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Lipitor Lawsuit Diabetes Information Center, http://www.lipitorlawsuitcenter.com/, +1 800-511-5092, [email protected]
Share this article